Parasites of the genus Plasmodium are the causative agents of malaria, man’s most lethal parasitic disease. Each year, millions of people in tropical and subtropical regions of the world are infected with malaria parasites and approximately 1 million of these infections result in death [1,10]. While four Plasmodium species commonly infect humans, the two that cause the most morbidity and mortality are Plasmodium falciparum and Plasmodium vivax. P. falciparum is the cause of most deaths, which occur mainly in children and pregnant women in sub-Saharan Africa [2,3]. P. vivax, although it causes relatively fewer deaths, is responsible for significant morbidity, particularly in South America and the Asia–Pacific region [4].

Much of the current antimalarial pharmacopeia was identified serendipitously and, unlike current target-based drug discovery programs, the mode of action of these agents is still poorly understood. Quinine, the first widely used antimalarial agent, derived from the bark of the Cinchona tree and first isolated in 1820 [5,6], and now artemisinin (also known as qinghaosu), an extract of sweet wormwood (Artemisia annua) [6,7], are derived from long-established herbal remedies from South America and China, respectively. Many of the antimalarial drugs in common use today are structural derivatives of these agents.

Despite the availability of effective antimalarial drugs, the prevention and treatment of malaria is progressively becoming more difficult due to the global spread of drug resistance. Almost all P. falciparum parasites are resistant to chloroquine [8], and other affordable antimalarial drugs such as sulfadoxine/pyrimethamine are becoming less effective [9,10]. The recent emergence of tolerance to the artemisinin drugs [11,12] is also of great concern and highlights the ongoing need for drug development. Thus, new antimalarial agents that act against novel parasite targets are required to combat multidrug-resistant parasites.

Malaria parasites have a complex life cycle and there are a number of key stages that are targeted by current antimalarial drugs and are potential targets for new drugs. The life cycle of P. falciparum is shown in Figure 1. Infection in humans begins when an infected female anopheles mosquito feeds and injects sporozoites into the host’s bloodstream. These sporozoites rapidly invade liver cells where they multiply extensively and form exoerythrocytic schizonts, each containing up to 30,000 merozoites. A total of 6–16 days after infection (depending on the species), the schizont-infected hepatocytes rupture, releasing mature merozoites into the bloodstream. These...
merozoites invade red blood cells (RBCs) and undergo a second round of multiplication that lasts 48–72 h and produces up to 32 merozoites. The released merozoites invade new RBCs and continue the asexual replication cycle.

The asexual erythrocytic lifecycle of *P. falciparum* is relatively synchronous in the natural host, lasting for 48 h. In synchronous infections, the rupture of the infected RBCs and merozoite release are associated with the characteristic fever and acute symptoms of malaria. Some merozoites also give rise to sexually differentiated forms (gametocytes). The trigger for gametocytopsis is unclear. When a female anopheles mosquito ingests the blood of a host containing malaria parasites, the RBCs and asexual stage parasites are digested, while the gametocytes undergo further development to form macrogametocytes (female) or microgametocytes (male). In the mosquito gut, the male and female gametes fuse to form a diploid oocyste (the parasite is haploid during the rest of the lifecycle). As the oocyst matures, it divides to produce sporozoites, which travel to the salivary glands and are able to infect a new host when the mosquito next takes a blood meal.

Antimalarial drug development strategies often focus on targeting the asexual stages of *Plasmodium* development [6,11–13]. These intra-erythrocytic stages are metabolically active and display a number of biochemical pathways that are unique to the parasite. Although most of the currently available antimalarial drugs target asexual malaria parasites, they have different activities, pharmacokinetic characteristics and toxicity profiles. For these reasons treatment recommendations vary depending on the nature of the disease. The WHO currently classifies malaria treatment into two categories: uncomplicated malaria and severe malaria [102]. To address these recommendations, organizations such as the Medicines for Malaria Venture have created seven drug target profiles [14]:

- Treatment of uncomplicated *P. falciparum* malaria
- Non-oral treatment of complicated/severe *P. falciparum* malaria in adults and children
- Treatment of *P. vivax* malaria
- Intermittent preventative treatment (IPT) in pregnant women
- IPT in infants
HDAC inhibitors have been widely evaluated for expression. They act together with histone acetlytransferases ing eukaryotic cell chromatin structure, transcription and gene expression. Histone deacetylases are enzymes that are involved in regulating gene transcription and other proteins to alter the acetylation of the lysine side chains of histones [22–24]. Paradoxically, the inhibition of histone deacetylation can both activate and suppress the transcription of genes [25,26]. HDAC inhibitors have been widely evaluated for their therapeutic properties (for recent reviews see [27,28]) and so they might represent attractive targets for antimalarial drugs that act by a novel mechanism.

While there are at least five HDAC homologues/orthologues in \textit{P. falciparum} [29–34], the focus of drug discovery efforts to date has been on the PfHDAC1 protein. PfHDAC1 is expressed in intra-erythrocytic-stage parasites [29] and appears to have some subtle differences in the predicted enzyme active site entrance compared with human enzymes, which are being exploited for antimalarial drug discovery [35–38]. Promising \textit{in vitro} activities (low nM IC$_{50}$ values with very good selectivity in some cases) have recently been found for hydroxamate-class HDAC inhibitors against \textit{P. falciparum} parasites [39]. Many of these compounds were originally designed for use as anticancer agents [40,41]. Mode-of-action studies show that this class of compounds displays all the hallmarks of HDAC inhibitors against malaria parasites, including hyperacetylation of parasite histones and inhibition of \textit{in situ} and recombinant enzyme activities. Our ongoing development of this class of compounds is focusing on improving the pharmacokinetic profile.

**Taking advantage of the antimalarial activity of the HIV aspartic protease inhibitors**

It is becoming increasingly evident that the control of malaria depends not only on agents that target the intra-erythrocytic stages of parasite development, but also on the development of drugs that can inhibit additional stages of the parasite life cycle. Drugs that target gametocytes or at least prevent the development of these stages in the infected host are needed to control disease transmission, and drugs that target the pre-erythrocytic stages of parasite development are important as they can reduce the incidence of relapses and/or prevent infection altogether. Despite the growing appreciation of the need to target additional life cycle stages, most of the currently available antimalarial drugs and the majority of the drug development activities now underway focus on the asexual (blood) stages of parasite development [16,17,19]. One new group of antimalarial agents that might target multiple stages of \textit{Plasmodium} development via a mechanism of action different to all of the currently available antimalarial drugs are HIV AIs.

A number of studies have demonstrated that some AIs inhibit malaria parasite growth [42] and that the antimalarial activity of these drugs occurs at clinically relevant concentrations [43]. AIs inhibit the growth of malaria parasites in mice [44] and sera taken from HIV patients receiving AIs inhibits the growth of \textit{P. falciparum in vitro} [45]. Recent studies have demonstrated that AIs also possess activity against pre-erythrocytic stages [46]. Activity against a range of life cycle stages is unusual, and indicates that these drugs may represent a promising lead towards a new group of antimalarial agents that may reduce clinical disease and relapse. Their effect on gametocytogenesis and gametocytes has yet to be evaluated owing to the difficulty in evaluating drug studies on this stage of parasite development; although new methods are

- **Stand-by treatment in travelers**
- **Chemoprophylaxis**

Unfortunately, the discovery and development of new antimalarial drugs is a very long and involved process and in the end may not be successful for a number of reasons, including cost of synthesis, bioavailability and off-target effects. Many drugs aimed at the developed world are too expensive to be used in the low-cost environments that are characteristic of malaria endemic areas. However, a number of different strategies can be applied to antimalarial drug development to reduce cost. These include structural modification of existing drugs and ‘piggyback’ approaches that utilize drugs that have already been developed for other organisms or diseases, or act on a common target. An alternative is the \textit{de novo} identification of drugs that act against a novel target, or a combination of these approaches. Focusing on parasite-specific targets for which no human host homologue exists reduces the chance of drug toxicity. In 2002, the complete sequence of the first \textit{P. falciparum} clone was published [18]. This wealth of information has been instrumental in the identification of new molecular targets for the development of novel antimalarial chemotherapeutic agents. This review highlights the ongoing development of the targets that the authors have been investigating as potential avenues to exploit in the development of new drugs.

There are a number of new antimalarial agents in preclinical and clinical development that target both novel and classical parasite biochemical pathways (reviewed elsewhere [16–19]). Here, we discuss some different parasite molecular targets that may well lead to the future development of new chemotherapeutic agents.

**‘Piggyback’ drug discovery for malaria**

The piggyback antimalarial approach aims to identify agents that are either currently marketed or are being developed for treatment of other diseases, and usually have a common, or orthologous, target. An advantage of this approach is a potential cost-saving based on previous drug development investment for other diseases. However, given that drugs developed for diseases of wealthy nations are often expensive, even if they are relatively cheap to produce, some drugs may not be applicable to this approach unless patents have expired; for example, some antibiotics such as tetracyclines, which have antimalarial properties [20]. A good example of the piggyback approach in action is the exploitation of atovaquone. While this compound was initially shown to be an antimalarial, its activity against \textit{Pneumocystis} led to it being re-explored as an antimalarial, and now atovaquone combined with proguanil (Malarone\textsuperscript{TM}) is approved for malaria treatment and chemoprophylaxis [21]. Current examples of compounds being explored under the antimalarial piggyback approach are histone deacetylase (HDAC) inhibitors and HIV aspartic protease inhibitors (AIs).

**Histone deacetylase inhibitors: targeting gene transcription**

Histone deacetylases are enzymes that are involved in regulating eukaryotic cell chromatin structure, transcription and gene expression. They act together with histone acetyltransferases and other proteins to alter the acetylation of the lysine side chains of histones [22–24].
becoming available [47,48]. Very few antimalarial drugs are active against the pre-erythrocytic stage. The APIs saquinavir and ritonavir (at 4 μM) (Figure 2) also kill P. falciparum and P. vivax isolates taken directly from infected people [49]. These data, together with the in vivo data in mice [44], show that the antimalarial activity of APIs is not restricted to a single Plasmodium species.

In HIV, APIs inhibit the viral aspartyl protease, an essential enzyme for the production of mature HIV virions [50]. Data from a number of studies suggest that these drugs also kill malaria parasites by inhibiting an aspartyl protease (commonly referred to as a plasmeasin [PM] in malaria). The P. falciparum genome encodes ten aspartyl proteases. Four of these PMs are located in the food (digestive) vacuole (DV; PMI, PMII, PMIV and the histo-aspartic protease [HAP]) and are involved in hemoglobin digestion [51]. The six additional PMs have unknown functions. While recombinant enzyme assays demonstrate that high concentrations of the APIs saquinavir, lopinavir and ritonavir can inhibit the activity of the DV PMs PMII and -IV [52], other data support the hypothesis that these PMs are not the primary antimalarial targets of these drugs. Evidence for this hypothesis includes the demonstration that ritonavir and saquinavir behave antagonistically with E64, a well-characterized cysteine protease inhibitor, a characteristic that we would not expect of a DV PM inhibitor [43]. Furthermore, when the DV PMs PMI–IV are knocked out, both individually and collectively, the transgenic knockout parasites remain viable and retain their sensitivity to APIs [53–55].

Bootstrap analysis of the PMs suggests that the DV and non-DV PMs are not derived from a common ancestor in Apicomplexans [51], and may indicate a separate function for both groups. PMI, -II and -IV and HAP are clustered on chromosome 14, are expressed at high levels in blood-stage parasites and are localized to the DV where they participate in the digestion of hemoglobin [51]. The six remaining PMs are not clustered and appear to have different patterns of expression. PMV and -X have no introns and are likely to be related to PMI–IV. PlasmoDB [103] data suggest that P. falciparum PMs PMV, -VIII, -IX and -X are transcribed in blood-stage parasites. There was some discrepancy in the annotations of PMVIII by PlasmoDB and the Victorian Bioinformatics Consortium [104], with PlasmoDB predicting a much smaller protein; however, this now appears to have been rectified. While the expression profiles of PMV1 and -VII have yet to be experimentally confirmed, PlasmoDB data indicate that these PMs are primarily expressed in gametocytes, and are thus likely to be of less interest as a target of an intra-erythrocytic drug. PMV, -IX and -X are the only non-DV PMs that have been investigated, and only a few studies exist [56,57]. These studies have shown that PMV, -IX and -X are present in blood-stage parasites [56]. PMV is believed to be an integral membrane protein located in the endoplasmic reticulum [57]. Searches of P. vivax and Plasmodium chabaudi sequence data show that genes encoding similar proteins to P. falciparum PMs PMV, -VI, -VII, -IX and -X exist in P. chabaudi and P. vivax [103].

Taken together, these data suggest that notwithstanding any inhibition of PMI, -II, -IV and HAP, the APIs exert a major role in killing malaria parasites by inhibiting one of the nonfood vacuole blood-stage aspartyl proteases that have essential biological functions external to the food vacuole. However, which of these nonvacuole PMs that is/are the target(s) of the APIs has yet to be experimentally verified. By identifying and characterizing the target(s) of these drugs, we are paving the way for rational drug design. This process has been greatly aided by the numerous solid-state structures currently deposited in the Protein Data Bank database [105] and by the advances in in silico high-throughput screening [58], computational structure prediction methods [59], and molecular docking and scoring algorithms [60]. One problem that arises is that whist sequence identity of the Plasmodium aspartic proteases is relatively high across the family (~60%) [61], structural variation around the active site means that substrate specificity across the group is variable [62]. Classically, this would require the assembly of several different drug-like molecules – one for each target protein. Using solid state x-ray data and 3D-modeling techniques, Valiente et al. have reported the key seven residues (Y17, V105, T108, L191, L242, Q275 and T298 based on PMII numbering) required for PM function (Figure 3) [63].

These amino acids are conserved across the malarial strains but not in human aspartic proteases, suggesting that novel and selective antimalarial drugs can be developed that can better utilize these structural differences and may even allow the assembly of ‘adaptive’ drug molecules that have the ability to inhibit several members of a protein family at the same time [64]. This approach would not only reduce the ability of the organism to utilize redundant PM pathways for hydrolysis but, additionally, would drastically reduce the ability of the parasite to raise drug mutants as the organism would have to adapt multiple proteins concurrently. This has been realized to some extent in systems described by Nezami et al. who, using computer modeling and docking techniques, were able to rationalize the actual binding energies of a set of allopophenylorstatine-based compounds towards the four PM proteins outlined previously [65].

**Targeting de novo parasite pathways: purine salvage**

One approach to the development of new antimalarial drugs is to exploit differences in the basic biology of the host cell and the parasite for the de novo identification of drugs that act against a novel target. One such target is the purine salvage pathway of *P. falciparum*. In mammals, purine synthesis can occur de novo or by interconversion of salvaged purines, whereas the malaria parasite is totally dependent on purine salvage using purine bases obtained from the host. Like all intracellular parasites, *P. falciparum* is auxotrophic for purines and possesses elaborate purine salvage pathways to scavenge purines from their hosts [66]. A key role in this overall salvage process is played by the parasite’s purine phosphoribosyltransferases (PRTases). These enzymes catalyze the synthesis of purine nucleoside monophosphates from 5-phospho-α-d-ribose-1-pyrophosphate (Prib-PP) and the corresponding purine base [67–69].

One PRTase enzyme that has specificity for a number of purine bases is hypoxanthine–xanthine–guanine phosphoribosyl transferase (HXGPRT), which can utilize hypoxanthine, guanine and xanthine as substrates (Km 0.46, 0.30 and 29 μM, respectively) [68]. HXGPRT catalyzes the synthesis of the 6-oxopurine mononucleotides IMP, XMP and GMP by transferring the nitrogen base
to the 1-β-position of the ribose ring of Prib-PP concomitant with the release of the pyrophosphate (PP) moiety. The mechanism by which this is accomplished is ordered: first, Prib-PP complexes with Mg^{2+}, followed by the binding of the purine base. PP then dissociates from the complex and the nucleoside monophosphate is released [70]. Like other metallo-enzymes, for catalysis to occur a divalent metal ion is required, usually Mg^{2+} [67].

HGXPRTs have several common structural features, including a conserved core domain and a less conserved hood domain. The active site is located at the boundary of these two domains.
The seven key
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
human and yeast MetAP1, in a high-throughput drug-screening program [79]. From this they identified a previously uncharacterized structural class of inhibitors containing a pyridine–pyrimidine core. The most potent compound, XC11, demonstrated a tenfold greater activity against PfMetAP1b (IC50: 0.7 µM) than against human MetAP2 (IC50: 7.0 µM), and exhibited little toxicity against human fibroblasts in a cell proliferation assay (IC50: 75 µM). XC11 was also over 100-fold more selective for the inhibition of PfMetAP1b when compared with PfMetAP1a and c. Most importantly, XC11 was active against both chloroquine-susceptible and -resistant *P. falciparum* in culture and *Plasmodium berghei* K175 in mice [79].

It follows that inhibitors against MetAP1 and MetAP2 of malaria parasites have potential as new antimalarial drugs, with the added prospect of creating potent crossovers or combined therapies that target several isoforms. Inhibitors of these enzymes could also be combined with inhibitors of other aminopeptidases (see later), in the event that this provides added benefit in either synergistic antimalarial activity or protection against the development of drug-resistant parasites.

**Neutral aminopeptidases**

Two neutral aminopeptidases have been identified in the annotated *P. falciparum* genome, a M1-family alanyl aminopeptidase (PfM1AAP) and a M17-family leucine aminopeptidase (PfM17LAP).

Functionally active recombinant PfM1AAP and PfM17LAP have been produced and characterized [80,81]. Biochemical studies of parasite extracts and the recombinant proteins indicate that these two enzymes can account for all of the neutral aminopeptidase activity characterized in soluble *P. falciparum* cytosolic extracts [80,81]. Assays using peptide substrates have revealed that while PfM1AAP and PfM17LAP are members of different protease families, they have overlapping substrate specificities. However, PfM1AAP exhibits broader substrate specificity than PfM17LAP. PfM1AAP’s broad substrate specificity is consistent with other M1 aminopeptidases, including the aminopeptidase Ns from Gram-positive bacteria [82]. In contrast to PfM1AAP, PfM17LAP preferentially cleaves substrates with N-terminally exposed hydrophobic amino acids, particularly leucine [80]. While a preference for leucine substrates has been described as a general feature of M17 leucyl aminopeptidases, PfM17LAP has a narrower substrate specificity than other characterized multitimeric eukaryotic LAPs [83]. The observation that PfM1AAP and PfM17LAP are redundant in their ability to release leucine from peptides suggests that this is a critical function within the malaria parasite. One possibility is that the leucine obtained by digestion of host hemoglobin-derived peptides (or other proteins) may be exchanged for extracellular isoleucine [84], the only amino acid not present in human hemoglobin, and one that cannot be synthesized by the parasite [85,86].

Bestatin, a fungal-derived antibiotic and a natural analog of the dipeptide Phe–Leu, is a potent inhibitor of *P. falciparum* neutral aminopeptidase activity. Bestatin inhibits the growth of *P. falciparum* both *in vitro* and *in vivo* [87,88], and appears to inhibit both PfM1AAP and PfM17LAP by chelating the active metal ions within their metal-binding centres [81,89,90]. Rationally designed phosphinate dipeptide analogs [81] also inhibit recombinant forms of these enzymes (rPfM1AAP and rPfM17LAP) more effectively than bestatin and are also active against *P. falciparum* in culture [89]. Furthermore, *in vivo* studies using a nonlethal *Plasmodium chabaudi chabaudi* murine malaria model have demonstrated that at least one of these compounds can reduce the parasite burden by up to 92%, as well as produce a 3-day delay in the appearance of parasites [89]. However, it is not clear which of the two enzymes plays a more significant role in parasite survival.

Transgenic parasites that overexpress each of the *P. falciparum* neutral aminopeptidases have been generated in an attempt to determine which, or if both, of these enzymes are the antimalarial target of bestatin and the phosphinate dipeptide analogs [81,91]. These studies have demonstrated that increased expression of either enzyme can protect them from drug-induced growth inhibition by these drugs and suggest that both *P. falciparum* neutral aminopeptidases are targeted by these drugs. The data also highlight the need to investigate the similarities and differences in the active site of these enzymes to enhance the prospects of developing potent antimalarial agents. The overlapping specificities of PfM1AAP and PfM17LAP for substrates could be exploited in the design of either specific and/or dual-acting inhibitors. Two specific inhibitors used in combination, or ideally a dual inhibitor, could have increased potency. Both enzymes are encoded by single-copy genes and no other neutral aminopeptidases exist in malaria parasites, indicating that issues of functional redundancy experienced with the DV proteases are unlikely to be a problem.

The x-ray crystal structure of rPfM1AAP was recently published [81] and has revealed some important characteristics that may allow the development of potent inhibitors of this enzyme. The zinc-binding and substrate-coordinating motifs of the enzyme are buried within catalytic domain II and have access to the external environment via two openings. The first opening is formed by domain IV, a helical and the C-terminal portion of the protease, and is large enough to permit substrate entry to the active site. The second opening formed by domains I and IV is much smaller and may represent the exit portal for released amino acids. The structure of rPfM1AAP also suggests that, in addition to the rational design of active site inhibitors, the creation of agents that block active site access (entry and exit) may be feasible. For example, blocking the exit of the released amino acids from this enzyme may prevent substrate access to the buried active site.

**Aspartyl aminopeptidase (M18AAP) & prolyl aminopeptidase (S33PAP)**

The two remaining aminopeptidases identified within the *P. falciparum* genome are an aspartyl and prolyl aminopeptidase. Compared with the two neutral aminopeptidases, M18AAP and S33PAP have a highly restricted substrate preference. M18AAP cleaves aspartic acid and, less so, glutamic acid from the N-terminus of proteins, while S33PAP will remove proline residues only [92].

The aspartyl aminopeptidases are classified as belonging to the M18 class. Unlike the M1 and M17 neutral aminopeptidases [80,81], few M18 class aspartyl aminopeptidases have been characterized. Our relatively poor understanding of these enzymes stems from the general lack of available substrate and inhibitor reagents; at present,
there is only limited information reported for the aspartyl amino peptidase of mammals [93], yeast [94] and bacteria [106].

The restricted specificity of M18AAP for the N-terminal acidic amino acids, aspartic and glutamic acid, which cannot be cleaved by any other aminopeptidases, makes them of particular interest. Owing to this specificity, it is assumed that they are involved in a housekeeping function in protein turnover, acting in concert with the cytosolic neutral aminopeptidases. We have proposed that the P. falciparum M18AAP works alongside the malarial M1 and M17 neutral aminopeptidases in the terminal stage of hemoglobin digestion, releasing free amino acids that are used by the rapidly growing intra-erythrocytic parasites for protein anabolism [80,90,91,95]. While the neutral aminopeptidases can release most hydrophobic and hydrophilic amino acids, they are ineffective against acid amino acids and, therefore, require the assistance of M18AAP.

However, a recent report indicates that P. falciparum M18AAP is not only expressed in the cytosol but is also exported to the parasitophorous vacuole of the parasite. This suggests that M18AAP may play an additional role, possibly in aiding rupture of the parasite from the cell. In support of this idea, Lauterbach et al. [96], using phage-display libraries, showed that the M18AAP bound to the human erythrocyte spectrin (a cytoskeletal) protein, and have subsequently identified a putative spectrin-binding motif [94]. Inhibition of the P. falciparum M18AAP using antisense RNA results in parasite growth abnormalities, vacuolarization and cellular damage [99]. Clearly, the M18AAP represents a target at which novel antimalarials that block its function(s) could be designed.

Similar to M18AAP, S33PAP has a highly restricted substrate preference. S33PAP can only remove proline residues from the N-terminus of proteins. Microarray analysis indicates that the expression of S33PAP is switched on earlier in the parasites development within the RBC than the other three non-methionine aminopeptidases and, therefore, this enzyme may have additional or separate function(s) to these enzymes. S33PAP is of particular interest as a potential target for drug development since, although detected in many microbes, this activity and genes encoding S33PAP enzymes have not been detected in mammals. Accordingly, S33PAP may be particularly attractive for the design of antimalarial inhibitors. While very little is known about the biology or biochemical characteristics of this enzyme, gene sequence analysis of the conceptually translated protein has revealed the presence of a protein export element (PEXEL) or vacular transit sequence thought to be involved in the transport of proteins across the parasitophorous vacuole membrane and into the red cell cytosol [97,98].

Conclusion
Malaria remains one of the most lethal diseases to humans. A new momentum for a global eradication program is gaining pace. However, drug resistance by the parasite is an ongoing issue, and without the advent of new and novel chemotherapeutic agents, this current eradication program may end in the same fashion as the last eradication program of the 1950s, with some successes but also many failures. The genome of P. falciparum has been sequenced and a number of potential drug targets have been identified. Rational drug design using both piggyback techniques as well as de novo identification will both play a role in the design of new antimalarial agents. Whether any of these agents will eventually become first-line drugs against the parasite depends on a number of factors, such as cost of raw materials, ease of synthesis, pharmacokinetics, stability and toxicity. Nonetheless, combination therapy to prevent the emergence of parasite resistance is also widely accepted as the only prudent course, and some of the targets outlined in this review may become part of combination therapies with existing agents.

Expert commentary
Given the urgent need to develop new antimalaria drugs, it is imperative that researchers identify novel biochemical pathways in malaria parasites that when disrupted with compounds are lethal to the parasite. The availability of the malaria genome (PlasmoDB) offers an invaluable platform from which these can be identified and from which molecular targets can be selected. However, production of functionally active recombinant forms of potential targets that can be exploited in structure analysis, the development of robust molecular assays and high-throughput drug screening present a major but not insurmountable problem. In this review, we have highlighted several examples of such targets, which may lead to the development of new antimalarial drugs, although there is a long way to go to before we inhibitory compounds that can be synthesized cheaply and have no off-target effects. Nevertheless, the continued investigation of such molecular targets adds to our database on what is and is not worth pursuing.

Five-year view
Malaria remains a devastating disease, with drug resistance an ongoing concern, particularly with reports of increased tolerance to artesinin in southeast Asia. There is a renewed emphasis on global ‘eradication’, and while this may be unrealistic in the short term, there has been significant progress in the last few years towards reducing the global burden of disease. There are currently a number of new chemotherapeutic agents/targets in the drug ‘pipeline’ at different stages of development. Some, like those outlined in this review, are still in the discovery phase and, realistically, a number of targets and their inhibitors will not progress further for reasons that plague all drug discovery programs. Nonetheless, within 5 years, the potential for a number of new or novel antimalarial agents to have been validated for use in humans is high. As the identification of novel proteins and metabolic processes unique to the parasite increases, new potential targets will also become available for investigation, thus preventing the same type of failures that beset the first global eradication program when chloroquine resistance first emerged.

Financial & competing interests disclosure
The authors thank the National Health and Medical Research Council of Australia, the Australian Research Council and Griffith University for funding support. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.
Key issues

- Malaria parasites infect millions of people in the tropics and subtropics, and every year approximately 1 million of these infections result in death.
- The prevention and treatment of malaria is becoming more difficult due to the global spread of drug-resistant parasites, and new antimalarial agents that act against novel parasite targets are needed.
- A number of strategies can be applied to antimalarial drug development. The ‘piggyback’ approach uses drugs already developed for other organisms or diseases and act on a common target. The de novo approach exploits differences in the basic biology of the host cell and the parasite in order to identify new drugs that act on a novel target. These approaches can be used in combination.
- Current examples of compounds being explored under the piggyback approach include histone deacetylase (HDAC) inhibitors and HIV aspartic protease inhibitors.
- HDAC inhibitors were originally designed for use as anticancer agents and are thought to act against malaria parasites by hyperacetylation of parasite histones and inhibition of enzyme activity. HIV aspartic protease inhibitors are currently used to treat HIV infection and are thought to kill malaria parasites by inhibition of an as yet unidentified essential nonfood vacuole, blood-stage aspartyl protease.
- Current examples of targets being explored under the de novo approach include the purine salvage pathway enzyme hypoxanthine–xanthine–guanine phosphoribosyltransferase and aminopeptidases important to protein anabolism and catabolism.
- Several aminopeptidases are also promising targets for the development of novel antimalarial drugs. These include the methionine aminopeptidases (PfMetAP1 and PfMetAP2), the neutral aminopeptidases (alanyl and leucyl), and aspartyl and prolyl aminopeptidases.
- Compounds that selectively block malaria methionine aminopeptidase 1b (PfMetAP1b) activity and exhibit activity against rodent malaria models in vivo have been identified. Similarly, compounds that target the neutral aminopeptidases in vitro and exhibit activity against rodent malaria models in vivo have also been identified.

References

Papers of special note have been highlighted as:

- of interest
- of considerable interest


- Indicates that resistance to artesunate may soon be a significant problem in southeast Asia.


• First publication identifying the antimalarial activity of HIV protease inhibitors.


**Websites**

101 World Malaria report http://apps.who.int/malaria/wmr2008

**Gives an overall picture of malaria today, along with the now positive outcomes that intervention is achieving in Africa.**


103 PlasmoDB. Plasmodium genome resource www.plasmodb.org/plasmo/home.jsp

104 WHO/TDR malaria database www.who.int/tdr/malaria database

105 RCSB PDB Protein data bank. A resource for studying biological macromolecules www.pdb.org

106 Min T, Shapiro L. Crystal structure of aminopeptidase (M18 family) from Thermolactica maritimi. RCSB Protein Database Reference 2GLF (2006) www.rcsb.org/pdb/explore.do?structureId=2GLF

**Affiliations**

- Donald L Gardiner
  Malaria Biology Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4006, Australia
- Tina S Skinner-Adams
  Malaria Biology Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4006, Australia
- Christopher L Brown
  School of Biomolecular and Physical Science, Griffith University, Nathan, QLD 4111, Australia
- Katherine T Andrews
  Griffith Medical Research College, a joint program of Griffith University and the Queensland Institute of Medical Research, Griffith University, Nathan, Australia and Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, Australia
- Colin M Stack
  School of Biomedical Health, Department of Medical Microbiology, University of Western Sydney, Narellan Road, Campbelltown, NSW 2560, Australia
- James S McCarthy
  Central Medical Division, School of Medicine, University of Queensland, St Lucia, Queensland, Australia and Clinical Tropical Medicine Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4006, Australia
- John P Dalton
  Institute of Parasitology, McGill University, 2111 Lakeshore Road, Sainte Anne de Bellevue, QC H9X 3V9, Canada
- Katharine R Trenholme
  Malaria Biology Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4006, Australia